high uptake in the symmetrical hilar and mediastinal adenopathy along with diffuse bone lesions involving the spine, acetabulum and sternum, raising the possibility of a sarcoid-like reaction secondary to malignancy. A sub-carinal biopsy subsequently demonstrated non-caseating epithelioid cell granulomas with no evidence of infective or malignant process, once again strongly suggestive of sarcoid. Granulomatous inflammation was also further demonstrated on a repeated attempt at bone marrow biopsy. He was then referred for a rheumatology opinion given the limited respiratory involvement in July 2017. Detailed history taking revealed a history of approximately 18 months of night sweats and insidious onset diffuse back pain. Due to his previous occupation an extensive infection screen was carried out including TB, toxoplasma, brucella, lyme and coxiella, all of which were negative. A serum ACE was 68 U/L (0-52 being the normal range). Following extensive serological testing for infective causes, he was started on prednisolone 40mg od in October 2017, which resulted in a dramatic improvement in his symptoms, namely back pain, fatigue and night sweats. Serum ACE normalised. The steroids were tapered after three months; however due to miscommunication the patient stopped it on Easter 2018. A few days later he developed florid synovitis affecting his left and right wrists along with his metacarpophalangeal joint. Steroids were recommenced and methotrexate started. A repeat PET-CT was organised, which confirmed significant interval regression in the intensity of FDG uptake in the spine with unchanged appearances of the lymphadenopathy. Further to this the gentleman rang the department to say he had stopped his methotrexate due to the development of a rash. He was also on amoxicillin for a presumed chest infection at the time. Due to the unclear association, DMARD therapy was changed to mycophenolate and he is currently on 500mg once a day, which isdue to be titrated up to 1g. Discussion: Up to 13% of patients with sarcoid present with radiologically evident skeletal involvement, but it is commonly appendicular. There are very few case report numbers of axial sarcoid as the primary presentation, especially sclerotic lesions. One of these reports a lady with Crohn's and pelvic sarcoma, whilst the other had a preceding diagnosis of pulmonary sarcoid along with lytic and sclerotic bone lesions. Treatment initiation was also difficult due to the rarity of such a presentation and the extraneous factors such as his occupational history lending to significant diagnostic difficulty. The case is interesting not only due to its rarity but also the possibility of this being a paraneoplastic phenomena. Key Learning Points: Multiple sclerotic lesions in a middle aged man are often a manifestation of metastatic malignancy. It is unusual to see axial sclerotic lesions as a primary manifestation of sarcoid, and it would be worthwhile lending credence to this differential in complex cases that don't fit the typical pattern. It would be of great value for the authors to learn of any similar cases encountered by our peers and their management challenges. Disclosure: R. Raghunath: None. R. Shah:None. E. Baguley:None. Rheumatology, Withybush General Hospital Haverfordwest, Haverfordwest, UNITED KINGDOM Introduction: A 43 year old male presented with history of shortness of breath, proximal muscle weakness, and pompholyx. He had a positive ENA, positive Jo-1 antibodies, raised CK. High-resolution computed tomography (HRCT) and VATS biopsy showed nonspecific interstitial fibrosis. These findings along with clinical features and investigations confirmed the diagnosis of antisynthetase syndrome (ASS). Case description:A 43 year old male with no significant past medical history was referred to rheumatology clinic with complaints of muscle weakness, shortness of breath on exertion, muscle aches particularly in his knees and generalised malaise. His exercise tolerance had significantly reduced from a normal active lifestyle to being unable to climb tanks as part of his work as an engineer on an oil refinery. He denied any chemical or asbestos exposure as part of his job. He was an ex-smoker (20 pack year's history), no alcohol use, no known allergies and did not take any regular medications. Physical examination revealed grade 1 clubbing; examination of the chest was unremarkable except the localised area of bronchial breathing in right base. Cardiovascular and abdominal examinations were unremarkable. On neurological examination, the only positive finding was proximal muscle weakness in the thighs. Routine blood tests including FBC, U&Es, LFT's were normal. His erythrocyte sedimentation rate was 19 (0-15 mm/hr) and C-reactive protein was normal. Creatine kinase (CK) levels were elevated at 575 (0-20 mg/L). Serum ferritin urinalysis, hepatitis serology, HIV screen were unremarkable. He had a negative rheumatoid factor (<20.0) but positive ENA result with positive
high uptake in the symmetrical hilar and mediastinal adenopathy along with diffuse bone lesions involving the spine, acetabulum and sternum, raising the possibility of a sarcoid-like reaction secondary to malignancy. A sub-carinal biopsy subsequently demonstrated non-caseating epithelioid cell granulomas with no evidence of infective or malignant process, once again strongly suggestive of sarcoid. Granulomatous inflammation was also further demonstrated on a repeated attempt at bone marrow biopsy. He was then referred for a rheumatology opinion given the limited respiratory involvement in July 2017. Detailed history taking revealed a history of approximately 18 months of night sweats and insidious onset diffuse back pain. Due to his previous occupation an extensive infection screen was carried out including TB, toxoplasma, brucella, lyme and coxiella, all of which were negative. A serum ACE was 68 U/L (0-52 being the normal range). Following extensive serological testing for infective causes, he was started on prednisolone 40mg od in October 2017, which resulted in a dramatic improvement in his symptoms, namely back pain, fatigue and night sweats. Serum ACE normalised. The steroids were tapered after three months; however due to miscommunication the patient stopped it on Easter 2018. A few days later he developed florid synovitis affecting his left and right wrists along with his metacarpophalangeal joint. Steroids were recommenced and methotrexate started. A repeat PET-CT was organised, which confirmed significant interval regression in the intensity of FDG uptake in the spine with unchanged appearances of the lymphadenopathy. Further to this the gentleman rang the department to say he had stopped his methotrexate due to the development of a rash. He was also on amoxicillin for a presumed chest infection at the time. Due to the unclear association, DMARD therapy was changed to mycophenolate and he is currently on 500mg once a day, which isdue to be titrated up to 1g. Discussion: Up to 13% of patients with sarcoid present with radiologically evident skeletal involvement, but it is commonly appendicular. There are very few case report numbers of axial sarcoid as the primary presentation, especially sclerotic lesions. One of these reports a lady with Crohn's and pelvic sarcoma, whilst the other had a preceding diagnosis of pulmonary sarcoid along with lytic and sclerotic bone lesions. Treatment initiation was also difficult due to the rarity of such a presentation and the extraneous factors such as his occupational history lending to significant diagnostic difficulty. The case is interesting not only due to its rarity but also the possibility of this being a paraneoplastic phenomena. Key Learning Points: Multiple sclerotic lesions in a middle aged man are often a manifestation of metastatic malignancy. It is unusual to see axial sclerotic lesions as a primary manifestation of sarcoid, and it would be worthwhile lending credence to this differential in complex cases that don't fit the typical pattern. It would be of great value for the authors to learn of any similar cases encountered by our peers and their management challenges. Disclosure: R. Raghunath: None. R. Shah:None. E. Baguley:None. Rheumatology, Withybush General Hospital Haverfordwest, Haverfordwest, UNITED KINGDOM Introduction: A 43 year old male presented with history of shortness of breath, proximal muscle weakness, and pompholyx. He had a positive ENA, positive Jo-1 antibodies, raised CK. High-resolution computed tomography (HRCT) and VATS biopsy showed nonspecific interstitial fibrosis. These findings along with clinical features and investigations confirmed the diagnosis of antisynthetase syndrome (ASS). Case description:A 43 year old male with no significant past medical history was referred to rheumatology clinic with complaints of muscle weakness, shortness of breath on exertion, muscle aches particularly in his knees and generalised malaise. His exercise tolerance had significantly reduced from a normal active lifestyle to being unable to climb tanks as part of his work as an engineer on an oil refinery. He denied any chemical or asbestos exposure as part of his job. He was an ex-smoker (20 pack year's history), no alcohol use, no known allergies and did not take any regular medications. Physical examination revealed grade 1 clubbing; examination of the chest was unremarkable except the localised area of bronchial breathing in right base. Cardiovascular and abdominal examinations were unremarkable. On neurological examination, the only positive finding was proximal muscle weakness in the thighs. Routine blood tests including FBC, U&Es, LFT's were normal. His erythrocyte sedimentation rate was 19 (0-15 mm/hr) and C-reactive protein was normal. Creatine kinase (CK) levels were elevated at 575 (0-20 mg/L). Serum ferritin urinalysis, hepatitis serology, HIV screen were unremarkable. He had a negative rheumatoid factor (<20.0) but positive ENA result with positive anti-Jo-1 antibodies (negative for anti-La, anti-RNP, and anti-Sm antibodies). ANA, ANCA, RNP, and scl-70 were negative. C3, C4 and immunoglobulin level were normal. A high resolution computed tomography (HRCT)scan showedreticularopacitiesbilaterallyinthe subpleuralareas, at the level of both lower lobes, dorsally and minor similar changes at the level of the right upper lobe, anterolaterally. Discrete patchy groundglass opacities seen at the dependent areas, in both lung bases. Overall appearances were most in keeping with non-specific interstitial pneumonitis (NSIP). The diagnosis of ASS in this patient was established on the basis ofthehistoryofpompholyxinthepast(although hehad nohyperkeratosis on the hand), Positive Anti Jo-1, NISP, myositis and raised CK. This patient was started initially on prednisolone and methotrexate following which he responded very well and his CK dropped down to normal, two years later he developed changes on HRCT suggestive of methotrexateinduced pneumonitis and methotrexate was withdrawn. He was treated with immunoglobulin infusion and steroid, but lung function tests continued to deteriorate. In view of this, he underwent VATs biopsy which showed NSIP pattern. He had cyclophosphamide in six cycles then MMF (mycophenolate mofetil) as maintenance therapy and advice from a center of excellence. Lung function tests improved significantly. Four years after presentation, he developed life-threatening CMV pneumonitis whilst on maintenance MMF 1g BD (commenced 22 months prior) and prednisolone 10mg once daily and was intubated and ventilated and required valganciclovir. HIV testing and testing for Pneumocystis carinii were negative. Subsequent testing showed an inadequate response to pneumonia and tetanus vaccinations and he developed herpetic lesions whilst on MMF 500mg daily and prednisolone 10mg daily and increasing immunosuppression was thought inadvisable. The recent development of EMG pattern consistent with myositis with a rise in total CK to 563 U/L has been treated with dose MMF and immunoglobulin infusion sixweekly. His lung function test in 2012 showed FEV1 3.88(91%), the FVC 4.43 (86%) Kco 85%, and TLco of 66< in 2012 while in December 2014 these figures were FEV1 4.16(99%) FVC 4.89(95%) Kco64%, and TLco of 52%. His last lung function test performed in September 2017 were FEV1 3.64 (89%) FVC 4.4 (88%) Kco 78%. Myositis improved significantly and he now cycles for 50 miles/weekregularly. Discussion: ASS is an immune-mediated disorder which is very rare (prevalence of 1.5 per 100.000 populations). Hallmark features consist of the combination of interstitial lung disease (ILD), myopathy, fever, and polyarthralgia. The autoimmune screenincludes anti-aminoacyl-transfer RNA synthetase positive more frequently that of anti-Jo-1 antibodywhich is present in approximately 80% of cases. Other less frequent antibodies in ASS are anti-PL-7 and anti-EJ.ILD is being reported in 80-90% of cases of ASS and lung involvement is thought to be the most important prognostic indicator. NSIP is the most frequently reported histological pattern in ASS and the presence of fibrosis is an adverse predictor for response to immunosuppressive therapies.Myositis is reported in 30-60% of ASS patients and anti-Jo-1 positivity can pre-date clinical myositis. Most treatment regimens for ASS describe a combination of glucocorticosteroids and other immunosuppressants such as cyclophosphamide with pulmonary disease response dictating treatment duration. Key Learning Points: Mycophenolate mofetil is increasingly used and experience in the renal transplant field suggests that although primary CMV infection is not more frequent than in other renal transplant patients not on MMF. The infection is more likely to be symptomatic. Rheumatologists should be alert to this potential diagnosis in patients treated with MMF. In summary, ASS is a rare systemic autoimmune condition characterized by a combination of ILD, myopathy, fevers, and polyarthralgia. HRCT typically shows an NSIP pattern and may help to suggestthe diagnosisinapatientpresenting with appropriate clinical features. Atypical infection may complicate the disease course when immunosuppressive agents are used. Disclosure: A. Nawaz: None. J. Barber:None. Y.Rashid: None. Introduction: Macrophage activation syndrome (MAS) is a rare but lifethreatening condition characterised by dysfunctional macrophage activation leading to overproduction of cytokines and phagocytosis of erythrocytes, leucocytes and platelets. Due to its mimicry of other conditions it is often under recognised leading to significant delays in diagnosis. We describe a case of a 42 year old lady with active systemic lupus erythematosus (SLE) who presented with lethargy, rash and joint pain and within 3 days of onset of significant cytopenias was diagnosed with MAS. This early diagnosis meant that her condition responded and resolved with less intensive immunosuppression.
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